

Maternal serum procalcitonin levels in prediction of chorioamnionitis in women with preterm premature rupture of membranes

Rabia Zehra Bakar¹, Nadiye Köroğlu², Lale S. Turkgeldi³, Esra N. Tola⁴, Berna Aslan Cetin², Ali Gedikbasi²

¹Department of Obstetrics and Gynecology, Erbaa State Hospital, Tokat, Turkey

²Department of Obstetrics and Gynecology, University of Health Sciences, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey

³Bahceci Assisted Reproductive Technology Centre, Istanbul, Turkey

⁴Department of Medicine, Suleyman Demirel University, Isparta, Turkey

Submitted: 21 January 2018

Accepted: 6 April 2018

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms.2019.86191>

Copyright © 2019 Termedia & Banach

Corresponding author:

Nadiye Köroğlu MD
Department of Obstetrics
and Gynecology
University of Health Sciences
Kanuni Sultan Suleyman
Training and Research
Hospital
Istanbul, Turkey
E-mail:
nadiye_dugan@hotmail.com

Abstract

Introduction: Chorioamnionitis is one of the most important maternal complications in the expectant management of patients with preterm premature rupture of membranes (PPROM). Procalcitonin (proCT), the precursor of the hormone calcitonin, is used to differentiate bacterial infections from non-bacterial ones. The objective of the study was to determine the efficacy of maternal serum procalcitonin levels in the early prediction of chorioamnionitis in women with PPRM.

Material and methods: The study was conducted in 76 pregnant women hospitalized due to PPRM at the maternal-fetal medicine unit of a tertiary center in Istanbul. Patients were followed up with white blood cell (WBC), C-reactive protein (CRP) and proCT levels every 2 days. The values of investigated parameters were recorded at the diagnosis of PPRM and at the time of delivery. The maximum values during the follow-up period were also recorded.

Results: Out of the 76 patients with PPRM, 15 (19.73%) developed clinical chorioamnionitis. No significant difference could be detected in the gravidity, parity, duration of hospitalization and gestational week at diagnosis between those patients who developed clinical chorioamnionitis and those who did not. The WBC at the time of hospital admittance and before delivery, and CRP levels before delivery were statistically higher in the chorioamnionitis group ($p < 0.05$). No difference in the proCT levels could be detected either at the time of hospital admittance or before delivery between the two groups.

Conclusions: Maternal proCT was not found to be predictive of chorioamnionitis. However, since there are reports in the literature that contradict these results, further studies are warranted to determine the true efficacy of proCT in the prediction of clinical chorioamnionitis.

Key words: preterm premature rupture of membranes, chorioamnionitis, procalcitonin, C-reactive protein.

Introduction

Preterm premature rupture of membranes (PPROM) is defined as the rupture of fetal membranes before 37 weeks of gestation and is encountered in 2–4% of singleton pregnancies [1, 2]. The mechanisms thought to be responsible for PPRM are overdistention of the uterus, ischemia, hemorrhage and most importantly infection and/or inflammation [3]. In the study by Goncalves *et al.*, amniotic cultures of patients with PPRM were found to be positive in 32.4% of cases. In contrast, microbial invasion was demonstrated in 75% of women at the time of delivery. This suggests that invasion takes place during the latent phase of labor [4]. Nevertheless, the majority of women with PPRM are asymptomatic at the time of diagnosis [5] and the American College of Obstetricians and Gynecologists recommends expectant management of such patients in the absence of maternal or fetal indications [1]. While the aim of expectant management in patients with PPRM is to reduce severe neonatal complications, the risk of maternal/fetal complications such as fetal distress, cord prolapse, placental abruption, and fetal and maternal infection is increased [6–8]. Chorioamnionitis also increases the risk of preterm birth, respiratory distress syndrome, bronchopulmonary dysplasia, cerebral palsy, periventricular leucomalacia and sepsis [9].

Clinical diagnosis of chorioamnionitis is made in the presence of at least two of the following findings: uterine tenderness, malodorous vaginal discharge, white blood cell (WBC) count of $> 20\,000/\text{mm}^3$, maternal fever $> 38^\circ\text{C}$, maternal ($> 120/\text{min}$) or fetal ($> 160/\text{min}$) tachycardia [10]. A large number of laboratory parameters including C-reactive protein (CRP) have been studied in the maternal serum, amniotic fluid and cervicovaginal samples of patients with PROM for the early diagnosis of chorioamnionitis. However, a laboratory test useful in the prediction of chorioamnionitis has not been found yet.

Procalcitonin (proCT) is an acute phase protein consisting of 116 amino acids and is the precursor of the hormone calcitonin [11]. It has gained acceptance in obstetric practice since it was shown to rise at 3 to 6 h following bacterial infections and is a sensitive biomarker that differentiates bacterial infections from non-bacterial ones and other inflammatory states [12]. In this study we aimed to determine whether maternal serum proCT levels are useful in the prediction of chorioamnionitis in patients with PPRM.

Material and methods

This study was conducted in 76 pregnant women admitted with a diagnosis of PPRM to the perinatology unit of the Health Sciences University Kanuni Sultan Suleyman Training and Research

Hospital in Istanbul between January 2016 and November 2016. The approval of the ethics committee was obtained from the Istanbul Bakirkoy Sadi Konuk Training and Research Committee (2016/13). All patients were informed in detail about the purpose and nature of the study and their written consent was obtained.

Patients' gestational weeks were determined according to their last menstrual period and first trimester ultrasounds. All patients underwent sterile speculum examinations and obstetric ultrasound evaluation. When amniotic fluid leakage was not evident, an Amnisure test was made to determine the presence of placental α -microglobulin-1 (PAMG-1) in cervicovaginal fluid samples. Patients at 24–34 weeks of gestation with a definitive diagnosis of PPRM were included in the study. None of the patients in the study population had any clinical findings or suspicion of chorioamnionitis at the time of hospital admittance.

The inclusion criteria were the absence of a history of preterm labor or premature rupture of membranes in previous pregnancies, a gestational age between 24 and 34 weeks and the absence of signs of chorioamnionitis. Patients presenting with fetal distress, patients who could not be followed up or had to be delivered immediately, those with fetal anomalies and clinical findings of chorioamnionitis were excluded from the study.

The age, gravidity, parity, gestational week at presentation and medical and obstetric histories were recorded. All patients underwent routine evaluation for vital signs and obstetric ultrasound examinations. Blood was drawn for WBC, CRP and proCT evaluations.

During clinical follow-up, patients received prophylactic antibiotherapy (ampicillin-sulbactam 1 g 4×1 *i.v.* for 2 days, followed by sultamicillin 375 mg 2×1 for at least 5 days) and corticosteroids for fetal lung maturation (12 mg betamethasone, twice, 24 h apart). Patients were followed up with vital signs and laboratory tests during hospitalization. WBC, CRP and proCT tests were repeated every two days. The blood drawn for proCT evaluation was centrifuged and analyzed with the Elecsys Brahms proCT kit. The presence of maternal fever ($> 38^\circ\text{C}$) not otherwise explained by other factors, maternal tachycardia ($> 100/\text{min}$), fetal tachycardia ($> 160/\text{min}$), uterine tenderness and malodorous vaginal discharge was determined as clinical chorioamnionitis. The diagnosis of chorioamnionitis was made by clinical signs as described previously.

Statistical analysis

Data were analyzed using the SPSS 23.0 program. Tests of normality of continuous variables were made using the Kolmogorov-Smirnov and

Shapiro-Wilk tests. The relationship between continuous variables and presence of chorioamnionitis was evaluated using the Mann-Whitney *U* test. A value of $p < 0.05$ was considered to be statistically significant. To evaluate the predictive effect of investigated markers on the development of chorioamnionitis, multivariate regression analysis was performed.

The optimal cut-off points of investigated markers (CRP, WBC and proCT) were determined by receiver operating characteristic (ROC) analyses. Sensitivity and specificity were also calculated at the best cut-off point. To determine whether investigated markers were independently predictive for the diagnosis of chorioamnionitis, multivariate regression analysis was used.

Results

Among 76 patients with PPRM included in the study, 15 were found to develop chorioamnionitis with a rate of 19.7%. The mean gestational weeks at the time of delivery of the 61 patients who did not develop chorioamnionitis (considered as the control group) and 15 who did develop chorioamnionitis were 32.62 ± 3.7 and 30.4 ± 3.22 , respectively. Although patients with chorioamnionitis were delivered at an earlier gestational week than those without chorioamnionitis, this difference was not statistically significant ($p = 0.054$) (Table I).

A diagnosis of chorioamnionitis was made in the presence of certain clinical findings. The first

blood levels obtained at the time of admittance, the last levels obtained before delivery and the maximum levels during the follow-up period of CRP, proCT and WBC were recorded. The laboratory results of patients with clinical chorioamnionitis and those without chorioamnionitis are compared in Table II.

The pre-delivery (last) CRP levels were statistically significantly higher in the chorioamnionitis group than the non-chorioamnionitis group ($p = 0.004$). In the group of patients who developed chorioamnionitis, the mean CRP level was 59.63 ± 73.99 mg/l while the mean CRP level in patients who did not develop chorioamnionitis was as low as 8.87 ± 9.12 mg/l (Table II).

WBC levels obtained at the time of admittance and the last parameter prior to delivery were significantly higher in the chorioamnionitis group than the non-chorioamnionitis group ($p = 0.011$, $p < 0.0001$, Table II).

ProCT levels obtained at the time of PPRM diagnosis, at the time of delivery and maximum levels during the follow-up period did not differ significantly between chorioamnionitis and non-chorioamnionitis group (Table II).

The ROC analysis of serum WBC and CRP for the diagnosis of chorioamnionitis is shown in Figures 1 and 2. The areas under the curve for WBC and CRP were 0.714 and 0.744, respectively. The best cutoffs for serum WBC and CRP were 13.4 G/l and 9.1 mg/l, respectively. Serum values of WBC greater than this threshold had 80% sensitivity

Table I. Clinical characteristics of patients with chorioamnionitis and without chorioamnionitis

Characteristic	Chorioamnionitis positive (n = 15)	Chorioamnionitis negative (n = 61)	P-value
Age [years]	31.07 \pm 6.27	28.88 \pm 6.62	0.3
Gravidity (n)	3.33 \pm 1.99	3.05 \pm 1.68	0.6
Parity (n)	1.93 \pm 1.79	1.36 \pm 1.2	0.3
Gestational week at administration	28.33 \pm 2.97	28.69 \pm 2.97	0.6
Duration of hospitalization [days]	13.93 \pm 13.43	17.43 \pm 13.98	0.2
Gestational week at delivery	30.40 \pm 3.22	32.62 \pm 3.74	0.054

Table II. Comparison of laboratory parameters in patients with chorioamnionitis and without chorioamnionitis

Parameter	Chorioamnionitis positive (n = 15)	Chorioamnionitis negative (n = 61)	P-value
First CRP	15.7 \pm 22.36	6.74 \pm 7.8	0.6
First proCT	0.05 \pm 0.03	0.04 \pm 0.02	0.051
First WBC	15.14 \pm 3.21	12.68 \pm 3.62	0.01
Last CRP	59.63 \pm 73.99	8.87 \pm 9.12	0.004
Last proCT	0.2 \pm 0.42	0.05 \pm 0.02	0.4
Last WBC	16.87 \pm 4.28	12.56 \pm 3.52	< 0.0001
Max. proCT	0.2 \pm 0.4	0.06 \pm 0.02	0.3

Covariates: first CRP, first proCT, first WBC, last CRP, last proCT, last WBC, max proCT, CRP – C-reactive protein, proCT – procalcitonin, WBC – white blood cells, first – at the time of the diagnosis of preterm premature rupture of membrane, last – at the time of delivery, max. – maximum value of proCT during the follow-up period.




Figure 1. ROC curve for WBC at the time of the diagnosis of PROM for prediction of the development of chorioamnionitis




Figure 2. ROC curve for serum CRP levels at the time of delivery for prediction of the development of chorioamnionitis

and 61% specificity and CRP had 66% sensitivity and 68% specificity for the diagnosis of chorioamnionitis. The best cutoff for serum proCT was 0.036 and values greater than this threshold had 53% sensitivity and 30% specificity.

We also evaluated the predictive effect of investigated parameters for the development of chorioamnionitis. When first CRP, first proCT, first WBC, last CRP, last proCT, last WBC, and max proCT were taken as covariates, a negative predictive effect of first proCT ($\beta = -82$, OR = 0.00001, 95% CI: 0.00001–0.0001), $p = 0.02$) and a positive predictive effect of first WBC ($\beta = -0.30$, OR = 1.353, 95% CI: 1.02–1.78), $p = 0.03$) and last CRP ($\beta = 0.06$, OR = 1.068, 95% CI: 1.01–1.12, $p = 0.01$) were found. Related data are shown in Table III.

Discussion

In this study we evaluated the efficacy of maternal serum proCT levels in the prediction of chorioamnionitis, a condition which can develop during the follow-up period of patients with PPROM and lead to severe maternal and fetal complications. The clinical chorioamnionitis rate

in this study was 19.7%, in accordance with the rates of 15–25% reported in the literature [13]. The first and last WBC levels obtained at admittance and just before delivery and the last CRP levels obtained before delivery were significantly higher in patients with chorioamnionitis than patients without chorioamnionitis. However, proCT levels at the time of hospital admittance and the last levels obtained before delivery, and the maximum level of proCT were not statistically significantly different between the two groups.

C-reactive protein is an acute phase protein secreted by the liver in response to inflammation, but it is not specific to infectious conditions. Even though there are contradictory data on its actual usefulness, it is a frequently used clinical parameter in the diagnosis of chorioamnionitis. Fisk *et al.* reported a significant relationship between increased CRP levels and histological diagnoses of chorioamnionitis. When cut-off values of 30, 35, and 40 mg/l are used, the predictive value of CRP for chorioamnionitis was reported to be higher. At levels below 20 mg/l, CRP measurements in patients with infection and those without were

Table III. Predictive effect of proCT, CRP and WBC for the development of chorioamnionitis

Parameter	β	P-value	OR	95% CI for OR	
				Lower	Upper
First proCT	-82	0.02	0.00001	0.00001	0.0001
First WBC	0.30	0.03	1.353	1.02	1.78
Last CRP	0.06	0.01	1.068	1.01	1.12
Constant	-3.89	0.07	0.02		

proCT – procalcitonin, WBC – white blood cells, CRP – C-reactive protein, first – at the time of the diagnosis of preterm premature rupture of membrane, last – at the time of delivery.

found to overlap and the diagnostic value of CRP was found to be limited [14]. Similarly, Nowak *et al.* used two different cut-off values for CRP (12 vs. 20 mg/l) and reported 12 mg/l to be a reliable cut-off value when serial samples are obtained [15]. Furthermore, Trochez-Martinez *et al.* reported in their systematic review that CRP would be predictive of chorioamnionitis above cut-off values of at least 30 mg/ml if a single blood analysis is to be made, and above 20 mg/ml if serial blood analyses are to be made [10]. In contrast, many other studies have found CRP to be insufficient in the diagnosis of chorioamnionitis [16–20]. In their study comparing patients with histologically confirmed chorioamnionitis with those without chorioamnionitis Sereepapong *et al.* reported no difference in CRP levels but a significant difference in maternal leucocyte (WBC) and neutrophil levels when they used cut-off values of 0.5 mg/dl, 15 G/l, and 80% for CRP, leucocyte number and neutrophil percentage, respectively. The sensitivity and specificities were found to be 56% and 58% for CRP; 60% and 63% for leucocyte number and 62% and 54% for neutrophil percentage, respectively [19]. In the present study we found the sensitivity and specificities for WBC at the time of hospital admittance to be 46% and 80.3% and for WBC obtained before delivery to be 73.3% and 77.05%, respectively. These findings indicate that chorioamnionitis should be suspected when leucocyte count rises above 15 G/l even in the absence of clinical findings. When a cut-off value of 5 mg/l is used, the sensitivity and specificity of CRP for the early diagnosis of chorioamnionitis was found to be 60% and 47% in accordance with those reported in the literature [21, 22].

ProCT is a biomarker which increases in response to bacterial infections. However, it does not increase significantly in response to viral or non-infectious inflammations. It is also shown that proCT can be used as a guide both for initiation and discontinuation of antibiotic therapy. Its production is increased in all parenchymal tissues in the presence of bacterial infections and the degree of increase in serum levels is related to the severity of the infection [23]. Torbe *et al.* reported that proCT from vaginal secretions was a more valuable marker of subclinical infection in patients with PPRM than those with PROM. They also found the sensitivity and specificity of proCT in vaginal secretions to be 25% and 50% respectively, when a cut-off value of 2.2 ng/ml was used for the diagnosis of histologic chorioamnionitis. However, they still found vaginal proCT to be insufficient in the early diagnosis of histologically confirmed chorioamnionitis in patients with PPRM and suspicion of subclinical intrauterine infection [24].

Torbe *et al.* reported the sensitivity of maternal serum proCT for the early diagnosis of neonatal infection and histological chorioamnionitis to be 53% and 75%, and the specificity to be 45% and 45%, respectively, when a threshold value of 1.9 ng/ml was used [24]. They concluded that maternal serum proCT is insufficient in the diagnosis of histologically confirmed chorioamnionitis and in patients with PPRM with suspected intraamniotic infection [24]. In the current study, sensitivity and specificity for proCT in diagnosis of chorioamnionitis are low when a threshold value of 0.036 ng/ml is used. However, it should be kept in mind that a low or normal proCT does not exclude bacterial infections especially in localized infections such as chorioamnionitis.

In contrast, Oludag *et al.* reported the sensitivity and specificity of proCT in the early diagnosis of histological chorioamnionitis as 92.3% and 68.4% respectively, when a threshold value of 0.054 ng/ml was used. Because proCT was found to have a higher specificity than CRP in the early diagnosis of histological chorioamnionitis, they concluded that proCT is more useful during follow-up of patients with PPRM than CRP [22]. Similarly, Kuyumcuoğlu *et al.* found cervicovaginal liquid proCT, maternal serum CRP, and WBC levels to be significantly higher in patients with chorioamnionitis and suggested that proCT measurements may be useful in the diagnosis of intrauterine infection in patients with PPRM [25].

In conclusion, in the present study the sensitivity, specificity and positive and negative predictive values of proCT for the diagnosis of chorioamnionitis when a threshold value of 0.5 ng/ml was used were 14.3%, 100%, 100% and 83.56%, respectively. The possibility of chorioamnionitis with a proCT value below 0.5 ng/ml is quite low. The discrepancy between the results of studies reported in the literature is thought to be due to non-standardized proCT measurement techniques that differ from one laboratory to another.

One of the limiting factors of the present study is the small study population. Another limitation is the fact that the correlation between neonatal outcomes and proCT levels has not been evaluated.

Conflict of interest

The authors declare no conflict of interest.

References

1. ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 80: Premature rupture of membranes. Clinical management guidelines for obstetrician gynecologists. *Obstet Gynecol* 2007; 109: 1007-19.
2. Ohlsson A. Treatments of preterm premature rupture of membranes: a metaanalysis. *Am J Obstet Gynecol* 1989; 160: 890-906.

3. Blumenfeld YJ, Lee HC, Gould JB, Langen ES, Jafari A, El-Sayed YY. The effect of preterm premature rupture of membranes on neonatal mortality rates. *Obstet Gynecol* 2010; 116: 1381-6.
4. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. *Ment Retard Dev Disabil Res Rev* 2002; 8: 3-13.
5. Romero R, Quintero R, Oyarzun E, Wu YK, Sabo V, Mazor M, Hobbins JC. Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. *Am J Obstet Gynecol* 1988; 159: 661-6.
6. Philipson EH, Hoffman DS, Hansen GO, Ingardia CJ. Preterm premature rupture of membranes: experience with latent periods in excess of seven days. *Am J Perinatol* 1994; 11: 416-9.
7. Mercer BM, Goldenberg RL, Meis PJ, et al. The Preterm Prediction Study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 2000; 183: 738-45.
8. French JJ, McGregor JA. The pathobiology of premature rupture of membranes. *Semin Perinatol* 1996; 20: 344-68.
9. Metcalfe A, Lisonkova S, Sabr Y, Stritzke A, Joseph KS. Neonatal respiratory morbidity following exposure to chorioamnionitis. *BMC Pediatr* 2017; 17: 128.
10. Trochez-Martinez RD, Smith P, Lamont RF. Use of C-reactive protein as a predictor of chorioamnionitis in preterm prelabor rupture of membranes: a systematic review. *BJOG* 2007; 114: 796-801.
11. Perrakis A, Stirkat F, Croner RS, et al. Prognostic and diagnostic value of procalcitonin in the post-transplant setting after liver transplantation. *Arch Med Sci* 2016; 12: 372-9.
12. Fadel FI, Elshamaa MF, Elghoroury EA, et al. Usefulness of serum procalcitonin as a diagnostic biomarker of infection in children with chronic kidney disease. *Arch Med Sci Atheroscler Dia* 2016; 1: e23-31.
13. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. *Cochrane Database Syst Rev* 2010; 8: CD001058.
14. Fisk N, Fysh J, Child A, Gatenby P, Jeffery H, Bradfield A. Is C-reactive protein really useful in preterm premature rupture of the membranes? *Br J Obstet Gynaecol* 1987; 94: 1159-64.
15. Nowak M, Oszukowski P, Szpakowski M, Malinowski A, Maciolek-Blewniewska G. Intrauterine infections. I. The role of C-reactive protein, white blood cell count and erythrocyte sedimentation rate in the prediction of chorioamnionitis in cases of premature rupture of membranes. *Ginekol Pol* 1998; 69: 615-22.
16. Bankowska E, Leibschang J, Pawlowska A. Usefulness of determination of granulocyte elastase plasma level, C-reactive protein and white blood cell count in prediction of intrauterine infection in pregnant women after PPROM. *Ginekol Pol* 2003; 74: 1037-43.
17. Farb H, Arnesen M, Geistler P, Knox E. C-reactive protein with premature rupture of membranes and premature labor. *Obstet Gynecol* 1983; 62: 49-51.
18. Kurki T, Teramo K, Ylikorkala O, Paavonen J. C-reactive protein in preterm premature rupture of the membranes. *Arch Gynecol Obstet* 1990; 247: 31-7.
19. Sereepapong W, Limpongsanurak S, Triratanachat S, Wannakrairot P, Charuruks N, Krailadsiri P. The role of maternal serum C-reactive protein and white blood cell count in the prediction of chorioamnionitis in women with premature rupture of membranes. *J Med Assoc Thai* 2001; 84: 360-6.
20. Yoon B, Jun J, Park K, Syn H, Gomez R, Romero R. Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. *Obstet Gynecol* 1996; 88: 1034-40.
21. Torbé A. Maternal plasma procalcitonin concentrations in pregnancy complicated by preterm premature rupture of membranes. *Mediators Inflamm* 2007; 35: 782-7.
22. Oludag T, Gode F, Caglayan E, Saatli B, Okyay RE, Altunyurt S. Value of maternal procalcitonin levels for predicting subclinical intra-amniotic infection in preterm premature rupture of membranes. *J Obstet Gynaecol Res* 2014; 40: 954-60.
23. Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. *Clin Biochem Rev* 2017; 38: 59-68.
24. Torbe A, Czajka R. Are vaginal fluid procalcitonin levels useful for the prediction of subclinical infection in patients with preterm premature rupture of membranes? *J Obstet Gynecol Res* 2005; 31: 464-70.
25. Kuyumcuoglu U, Kangal K, Guzel AI, Celik Y. Clinical significance of procalcitonin in cervico-vaginal secretions of women with preterm rupture of membranes. *Clin Exp Obstet Gynecol* 2010; 37: 319-21.